- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07600307
Evaluating a Digital Toolkit for IPV
14 maj 2026 uppdaterad av: Medical University of South Carolina
A Stepped-Wedge Randomized Controlled Trial Evaluating a Digital Toolkit for IPV
The study evaluates a web-based digital toolkit designed to screen for intimate partner violence (IPV), post-traumatic stress disorder (PTSD), and related mental health concerns within opioid treatment programs.
Providers use the toolkit during routine care with patients receiving treatment for opioid use disorder.
The study examines how the toolkit is implemented into clinic workflows and whether its use improves detection, referral, and patient outcomes.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
792
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Ariel Worley, MPH
- Telefonnummer: (843) 792-8208
- E-post: worleyar@musc.edu
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion criteria for all participants:
- Age 18 and older
- Able to understand and sign a consent form in English
Inclusion criteria for OTPs:
- Current experience working in one of the three opioid treatment clinics serving as a recruitment site for this study
- Health care professional training (e.g., social worker, counselor, physician, psychologist, nurse practitioner)
Exclusion criteria for OTPs:
- None
Inclusion criteria for patients with OUD:
- Report opioids as their primary substance of use for which they are seeking treatment
- Receive treatment at one of the three opioid treatment clinics serving as a recruitment site for this study
Exclusion criteria for patients with OUD:
- An acute medical problem requiring inpatient treatment (e.g., detoxification)
- Incarceration at the time of the study
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Undersökning
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Treatment as Usual
Treatment as usual consists of screening and care practices as usual, as provided by the clinic setting
|
|
|
Experimentell: Digital Toolkit
Digital toolkit used for screening and providing referral/treatment planning information for intimate partner violence and mental health conditions
|
The digital toolkit intervention consists of validated tools to screen patients for intimate partner violence and mental health conditions and evidence-based suggestions for personalized treatment plans and/or referrals
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of patients who receive screening
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of patients seen who receive intimate partner violence and mental health screening
|
From enrollment until the end of study participation at (up to) 35 months
|
|
Proportion of patients screened positive for intimate partner violence
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of patients screened who screen positive for intimate partner violence
|
From enrollment until the end of study participation at (up to) 35 months
|
|
Proportion of intimate partner violence-positive patients who receive recommended or referred services
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of patients screened positive for intimate partner violence who received recommended or referred services for intimate partner violence
|
From enrollment until the end of study participation at (up to) 35 months
|
|
Proportion of patients retained on MOUD following intimate partner violence and mental health screening
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of patients retained in MOUD services for at least 18 months following intimate partner violence and mental health screening
|
From enrollment until the end of study participation at (up to) 35 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of providers completing intimate partner violence and mental health screening
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of providers completing intimate partner violence and mental health screening with at least 70% of eligible patients
|
From enrollment until the end of study participation at (up to) 35 months
|
|
Proportion of providers providing resources and referrals for patients who screened positive for intimate partner violence
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of providers who provided resources and/or referrals for patients who screened positive for intimate partner violence
|
From enrollment until the end of study participation at (up to) 35 months
|
|
Proportion of providers who had patients accept referrals and/or attempted to attend recommended psychosocial services
Tidsram: From enrollment until the end of study participation at (up to) 35 months
|
Proportion of providers for whom at least 60% of patients accepted referrals and/or attempted to attend recommended psychosocial services
|
From enrollment until the end of study participation at (up to) 35 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Utredare
- Huvudutredare: Amber M Jarnecke, PhD, Medical University of South Carolina
- Huvudutredare: Tanya C Saraiya, PhD, Medical University of South Carolina
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 december 2026
Primärt slutförande (Beräknad)
1 augusti 2030
Avslutad studie (Beräknad)
1 augusti 2030
Studieregistreringsdatum
Först inskickad
12 maj 2026
Först inskickad som uppfyllde QC-kriterierna
14 maj 2026
Första postat (Faktisk)
20 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
20 maj 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 maj 2026
Senast verifierad
1 maj 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Pro00151072
- 1R61DA061371 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Demographic, survey, and clinical data will be acquired.
The raw interview, survey, and clinical data will be stored within a secure computing environment.
All direct identifiers will be removed and maintained in a secure file.
All other scientific data (coded interview data, scale composites, recodes) will be both preserved and shared via ICPSR.
Documentation to be made available will include a study protocol, reference to study publication of primary outcomes, data sets, case report forms, a data dictionary, and study-specific notes.
Variables in the data dictionary will include a description, variable name, variable label, and standard codes for missing values.
Tidsram för IPD-delning
The first batch of data will be deposited 6 months after enrollment of the first participants and data will be deposited every 6 months thereafter until study completion.
The research community will have access to the full data set approximately 18 months following the end of the randomized clinical trial or after the primary paper has been accepted for publication, whichever happens first.
Kriterier för IPD Sharing Access
Data will be findable for the research community through ICPSR.
For all publications, an ICPSR study will be created and assigned a digital object identifier (DOI).
The DOI will be referenced in the publication to allow the research community to access the data used.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .